PolyPid Ltd. (PYPD): Price and Financial Metrics
PYPD Price/Volume Stats
| Current price | $5.04 | 52-week high | $41.40 |
| Prev. close | $5.30 | 52-week low | $4.62 |
| Day low | $4.62 | Volume | 3,390 |
| Day high | $5.04 | Avg. volume | 7,445 |
| 50-day MA | $9.25 | Dividend yield | N/A |
| 200-day MA | $14.89 | Market Cap | 3.28M |
PYPD Stock Price Chart Interactive Chart >
PolyPid Ltd. (PYPD) Company Bio
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.
Latest PYPD News From Around the Web
Below are the latest news stories about POLYPID LTD that investors may wish to consider to help them evaluate PYPD as an investment opportunity.
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferencePETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York. Cantor Global Healthcare Conference: Presentation Date: Thursday, September 28, 2023Presentation Time:8:00 AM Eastern Time The PolyPid management team |
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of HealthSuccessful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ GloballyPETACH TIKVA, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Israeli Ministry of Health has completed a successful Good Manufacturing Practice (GMP) audit of the Company's manufacturing facility without an |
PolyPid Announces Reverse Share SplitPETACH TIKVA, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders’ approval f |
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX100 NDA and MAA Regulatory Filings PETACH TIKVA, Israel, Sept. 19, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of the production of three process validation batches of D- |
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsReached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage bio |
PYPD Price Returns
| 1-mo | -40.11% |
| 3-mo | -53.46% |
| 6-mo | -63.48% |
| 1-year | -84.59% |
| 3-year | -98.67% |
| 5-year | N/A |
| YTD | -75.91% |
| 2022 | -87.85% |
| 2021 | -42.02% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...